Group launches Pfizer-backed awareness effort

Share this article:
Spurred on by the approval of Lyrica, the National Fibromyalgia Association is launching an educational campaign to raise awareness of the disorder, which affects an estimated 6 to 10 million Americans.

With backing from Pfizer and the services of Weisscomm Partners, the patient group rolled out a 30-second TV PSA, Web sites (fmaware.org, fibrohope.org) and a satellite media tour last month. The TV spot, produced by Pfizer agency Kaplan Thaler Group, features sufferers talking about their pain, with the text: “These people are not acting.” A voiceover says: “Imagine feeling this kind of pain, and no one knows what it is or believes you even have it.” It is airing nationally on cable and network TV.

“In our society, once you have an FDA-approved drug and a PSA, a condition becomes legitimate,” said NFA president Lynne Matallana. “It takes these things to reach enough people and make them understand the severity of the illness.”

Matallana was a partner at Diversified Marketing Concepts when she developed the condition in 1993. “I ended up spending two-and-a-half years in bed and seeing 37 doctors before I found a doctor who was able to diagnose,” she said.

An NFA survey of physicians found fewer than one-third of physicians felt confident in their ability to diagnose the disorder.

The group, which boasts 50,000 members, is partnering with physician and author Dr. Pamela Peeke who joined Matallana on the satellite media tour.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.